Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
China · Delayed Price · Currency is CNY 9.09
+0.12 (1.34%)
Sep 30, 2026, 3:00 PM CST
Tibet Weixinkang Medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,134 | 1,136 | 1,300 | 1,322 | 1,398 | 1,033 |
Other Revenue | - | - | 0.22 | 0.34 | 0.23 | 0.3 |
| 1,134 | 1,136 | 1,300 | 1,323 | 1,399 | 1,034 | |
Revenue Growth | -9.52% | -12.65% | -1.70% | -5.43% | 35.30% | 44.43% |
Cost of Revenue | 454.5 | 442.41 | 604.25 | 651.24 | 672.06 | 502.71 |
Gross Profit | 679.36 | 693.34 | 695.98 | 671.41 | 726.48 | 530.92 |
Selling, General & Admin | 377.93 | 356.32 | 347.42 | 403.84 | 483.97 | 389.59 |
Research & Development | 102.06 | 110.62 | 116.01 | 112.82 | 72.45 | 38.02 |
Other Operating Expenses | 44.38 | 8.86 | 10.45 | 11.8 | 15.29 | 11.94 |
Operating Expenses | 524.26 | 473.68 | 473.55 | 526.33 | 571.95 | 437.99 |
Operating Income | 155.11 | 219.67 | 222.43 | 145.07 | 154.54 | 92.92 |
Interest Expense | -0.29 | -0.22 | -0.22 | -0.34 | -0.19 | -0.11 |
Interest & Investment Income | 14.53 | 16.72 | 20.54 | 17.74 | 19.08 | 13.3 |
Currency Exchange Gain (Loss) | -0.12 | -0.01 | -0.1 | -0.13 | - | - |
Other Non Operating Income (Expenses) | -0.5 | -0.25 | -0.25 | -0.31 | -0.08 | -4.77 |
EBT Excluding Unusual Items | 168.71 | 235.9 | 242.39 | 162.02 | 173.34 | 101.34 |
Gain (Loss) on Sale of Investments | 10.6 | 19.79 | 2.97 | 11.58 | - | - |
Gain (Loss) on Sale of Assets | -0.23 | -0.08 | 0.01 | -0.57 | 0.13 | 0.06 |
Asset Writedown | -1.26 | -1.26 | -17.63 | - | -14.13 | -3.25 |
Other Unusual Items | 65.49 | 29.26 | 48.86 | 42.8 | 23.02 | 16.08 |
Pretax Income | 243.32 | 283.6 | 276.6 | 215.84 | 182.36 | 114.23 |
Income Tax Expense | 50.32 | 50.75 | 30.43 | 1.82 | 5.4 | 18.32 |
Earnings From Continuing Operations | 193 | 232.85 | 246.17 | 214.02 | 176.96 | 95.91 |
Net Income | 193 | 232.85 | 246.17 | 214.02 | 176.96 | 95.91 |
Net Income to Common | 193 | 232.85 | 246.17 | 214.02 | 176.96 | 95.91 |
Net Income Growth | -27.31% | -5.41% | 15.02% | 20.94% | 84.50% | 64.16% |
Shares Outstanding (Basic) | 430 | 431 | 432 | 428 | 432 | 417 |
Shares Outstanding (Diluted) | 430 | 431 | 432 | 428 | 432 | 417 |
Shares Change | -0.97% | -0.15% | 0.90% | -0.83% | 3.50% | -0.08% |
EPS (Basic) | 0.45 | 0.54 | 0.57 | 0.50 | 0.41 | 0.23 |
EPS (Diluted) | 0.45 | 0.54 | 0.57 | 0.50 | 0.41 | 0.23 |
EPS Growth | -26.59% | -5.26% | 14.00% | 21.95% | 78.26% | 64.29% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 157.33 | 101.62 | 314.61 | 170.3 | 168.46 | 115.09 |
Free Cash Flow Per Share | 0.37 | 0.24 | 0.73 | 0.40 | 0.39 | 0.28 |
Dividend Per Share | 0.327 | 0.327 | 0.342 | 0.285 | 0.235 | 0.160 |
Dividend Growth | -4.39% | -4.39% | 20.00% | 21.28% | 46.88% | 68.42% |
Gross Margin | 59.92% | 61.05% | 53.53% | 50.76% | 51.95% | 51.37% |
Operating Margin | 13.68% | 19.34% | 17.11% | 10.97% | 11.05% | 8.99% |
Profit Margin | 17.02% | 20.50% | 18.93% | 16.18% | 12.65% | 9.28% |
Free Cash Flow Margin | 13.88% | 8.95% | 24.20% | 12.88% | 12.04% | 11.13% |
EBITDA | 198.5 | 262.9 | 268.87 | 187.85 | 190.8 | 124.53 |
EBITDA Margin | 17.51% | 23.15% | 20.68% | 14.20% | 13.64% | 12.05% |
D&A For EBITDA | 43.39 | 43.24 | 46.44 | 42.78 | 36.27 | 31.6 |
EBIT | 155.11 | 219.67 | 222.43 | 145.07 | 154.54 | 92.92 |
EBIT Margin | 13.68% | 19.34% | 17.11% | 10.97% | 11.05% | 8.99% |
Effective Tax Rate | 20.68% | 17.89% | 11.00% | 0.84% | 2.96% | 16.04% |
Revenue as Reported | 1,134 | 1,136 | 1,300 | 1,323 | 1,399 | 1,034 |